Videos

Role of imaging modalities in the diagnosis and monitoring of age-related macular degeneration (AMD).

Carl Regillo, MD and Diana Do, MD, describe the progressive nature of age-related macular degeneration (AMD) and differences between dry AMD and wet AMD.

New phase 2 data show the potential of the biologic in patients at risk of acute pancreatitis progression, but with a need for better variable understanding.

Investigators discuss recently-published secondary sex-based assessments into PCI treatment, as well as their contribution to cardiovascular research action points that lessen the field's disparities.

Investigators discuss observed outcomes in females with high-risk PCI treatment, and their continued underrepresentation in pharmacologic studies.

Prescription rates of buprenorphine and opioid analgesics for OUD fell during the COVID-19 pandemic for new patients, but existing treatment was not affected.

Experts discuss patient factors and decision-making in choosing therapies for sickle cell disease.

Key opinion leaders focus on the use of crizanlizumab for painful crisis frequency in sickle cell disease.

A panel of experts in schizophrenic psychiatric care share their thoughts on the practice, patients, and treatment based on their years of experience.

Marla Dubinsky, MD, highlights currently available biologic therapies used to treat inflammatory bowel disease and describes where each option best fits into the therapeutic landscape.

Bempedoic acid monotherapy and its combination with ezetimibe for lipid lowering in patients intolerant to statins.

Role of dietary and lifestyle modifications as part of lipid management.

James Januzzi, MD, and Javed Butler, MD, MPH, MBA, discuss emerging agents, vericiguat and intravenous (IV) iron, in the treatment landscape for heart failure with reduced ejection fraction and advice for community physicians managing patients with heart failure.

A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.

Wally Smith, MD, gives insight on using voxelotor in patients during the COVID-19 pandemic.  

Looking at voxelotor in sickle cell disease, experts review the HOPE study.

Joe Avelino, RN, BSN, MHSA, CPHQ, and Rahn Bailey, MD, DFAPA, explain protocols a practice can follow when managing a patient with schizophrenia who is frequently hospitalized or has other medical conditions.

Rahn Bailey, MD, DFAPA, explains why long-acting injectables are under prescribed in patients with schizophrenia and why doctors choose not to use them as a first-line treatment.

A discussion on the uncovered benefits in risk reduction observed in patients with severe NDPR.

CDC data suggest ophthalmic patients are significantly more likely to present with a heart disease-driving condition or habit. How could preventive care improve?

An assessment of VISTA and VIVID patient data uncovered surprising risk factors associated with aflibercept success or failure in DME resolution.

The multidisciplinary panel of experts share final thoughts on strategies to normalize naloxone and decrease barriers to its obtainment and utilization.

Drs Marla Dubinsky and Stephen B. Hanauer discuss their treatment approaches for inflammatory bowel disease, highlighting the rationale for induction therapy versus maintenance therapy and considerations for using combination therapies.

Best practices for distinguishing between Crohn’s disease and ulcerative colitis when assessing patients who present with symptoms of inflammatory bowel disease and counseling patients and loved ones on treatment selection and goals. 

Dean Karalis, MD, provides expertise on the appropriate use of statins based on primary and secondary prevention.

Expert cardiologists express support for the uptake in the use of inclisiran once approved based on the cost-effectiveness.

Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, review additional mechanisms being investigated in the pipeline for the treatment of atopic dermatitis.

An expert discusses his interest in a pair of macular degeneration and diabetic macular edema treatments that may provide less burden and consistent efficacy in patients.